5,298 results on '"Barbaud A"'
Search Results
2. New Prostate Cancer Data Have Been Reported by M. Barbaud and Co-Authors (68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and ...)
- Subjects
Physical fitness ,Choline ,Cancer research ,Recurrence (Disease) -- Care and treatment ,Prostate cancer -- Care and treatment ,CAT scans ,Biochemistry ,Obesity ,Medical research ,Editors ,Health - Abstract
2019 NOV 30 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- A new study on Oncology - Prostate Cancer is now available. According [...]
- Published
- 2019
3. Delayed Skin Testing for Systemic Medications: Helpful or Not?
- Author
-
Barbaud, Annick, Goncalo, Margarida, Mockenhaupt, Maja, Copaescu, Ana, and Phillips, Elizabeth J.
- Published
- 2024
- Full Text
- View/download PDF
4. French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis)
- Author
-
Ingen-Housz-Oro, S., Matei, I., Gaillet, A., Gueudry, J., Zaghbib, K., Assier, H., Hua, C., Bensaid, B., Colin, A., Ouedraogo, R., Redlich, J., Courtois, E., Chazelas, K., Sbidian, E., Nakad, L., Bequignon, E., Terkmane, N., Gaultier, F., Schlemmer, F., Do-Pham, G., Barbaud, A., Lebrun-Vignes, B., Hoffmann, C., Mahé, P.-J., Le Floch, R., Bernier, C., Vabres, B., Milpied, B., Delcampe, A., Tétart, F., Tauber, M., Staumont-Sallé, D., Dezoteux, F., Descamps, V., Misery, L., Bursztejn, A.-C., Dereure, O., Amazan, E., Le Bidre, E., Le Pallec, S., Lagier, C., Laroche, A., Ferrat, E., Wolkenstein, P., and de Prost, N.
- Published
- 2024
- Full Text
- View/download PDF
5. Comparison of patients with isolated cutaneous lupus erythematosus versus systemic lupus erythematosus with cutaneous lupus erythematosus as the sole clinical feature: A monocentric study of 149 patients
- Author
-
Masseran, Clémence, Perray, Laura, Murat de Montai, Quitterie, Mathian, Alexis, Teboul, Alexandre, Francès, Camille, Arnaud, Laurent, Costedoat-Chalumeau, Nathalie, Amoura, Zahir, Courvoisier, Delphine S., Barbaud, Annick, and Chasset, François
- Published
- 2024
- Full Text
- View/download PDF
6. In Situ Patch Test and Repeated Open Application Test for Fixed Drug Eruption: A Multicenter Study
- Author
-
Traineau, Hélène, Milpied, Brigitte, Soria, Angèle, Assier, Haudrey, Tetart, Florence, Bernier, Claire, Le Bouëdec, Marie-Christine Ferrier, Gener, Gwendeline, Kurihara, Flore, Bauvin, Olivia, Delauney, Juliette, Amsler, Emmanuelle, Bara, Corina, Pelletier, Fabien, Valois, Aude, Castelain, Florence, de Risi Pugliese, Tullia, Hamelin, Aurore, and Barbaud, Annick
- Published
- 2024
- Full Text
- View/download PDF
7. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
- Author
-
Rosana, Agondi, Ahmed, Al Waily, Fabio, Almerigogna, Miguel Angel Tejedor, Alonso, Alfred, Ammoury, Eng Kim, Anne Goh, Robert, Anolik, Ledit, Ardusso, Petr, Arenberger, Nandini, AS, Mohammad, Asefi, Natalia, Astafieva, Anil, Badhwar, Esther Serra, Baldrich, Christine, Bangert, Annick, Barbaud, Zsuzsanna, Bata-Csorgo, Andrea, Bauer, Frederic, Berard, Beata, Bergler-Czop, Gary D, Berman, Jonathan, Bernstein, Subhash Chandra, Bharija, Ramesh M, Bhat, Isabelle, Boccon-Gibod, Ivan, Botev, Knut, Brockow, Philipp, Buck, Paula, Busse, Regis, Campos, Giorgio Walter, Canonica, Irani, Carla, Julia Maria Del, Carmen, Jaime Del, Carpio, Mamatha, Chadalavada, Yoon-Seok, Chang, Amarjit, Cheema, Yi Hsing, Chen, Yuko, Chinuki, Soyun, Cho, Jeong-Hee, Choi, Chia-Yu, Chu, Ronit, Confino, Jonathan, Corren, Roberta, Criado, Claudia De La, Cruz, David M, Cypcar, Pramila, Daftary, Inna, Danilycheva, Kenneth, Dawes, Michelle Joy, De Vera, James, Deangelo, Stefano, Del Giacco, Diana, Deleanu, John, Delgado, Richard, DeMera, Mohamed, Denguezli, Heinrich, Dickel, Le Huu, Doanh, Sinan, Dogan, Marie Sylvie, Doutre, Anne Sophie, Dupond, Anton, Edin, Kent, EDWARD, Swarna, Ekanayake-Bohling, Daniel, Elbirt, David, Elkayam, Anne, Ellis, Shaunagh, Emanuel, Alexander, Emeliyanov, Burhan, Engin, Luis Felipe, Ensina, Ignacio Antepara, Ercoreca, Safiye, Ergun, Jose Luis Lopez, Estebaranz, Rustem, Fassakhov, Daria, Fomina, Linda, Ford, Mariangela, Francomano, Todd, Funkhouser, Remi, Gagnon, Ricardo, Galimberti, Cesar Alberto, Galvan Calle, Clovis, Galvao, Gabriel, Gattolin, Pierre-Dominique, Ghislain, Ana Maria, Gimenez Arnau, Elliot, Ginchansky, Francoise, Giordano-Labadie, Stanislav, Givirovsky, Kiran, Godse, Shaila, Gogate, Alan, Goldsobel, Francisca, Gomez, Rene Maximiliano, Gomez, Erika, Gonzalez, Paula Ribo, Gonzalez, Dimitar, Gospodinov, Clive, Grattan, Martine, Grosber, Gary, Gross, Francisco Jose Gomez, Guimera Martin-Neda, Rolland, Gyulai, Svetlana, Hadvabova, Suzana Ljubojevic, Hadzavdic, Hadi, Hamam, Daniela, Hasicova, Koremasa, Hayama, Pravin, Hissaria, Anna, Hjerppe, Ivan, Hlinka, Moises Labrador, Horrillo, Connie, Hsu, Yu-Huei, Huang, Iftikhar, Hussain, Atsuyuki, Igarashi, Beata, IMKO-WALCZUK, Huseyin Serhat, Inaloz, Rossella, Intravaia, Neal, Jain, Sanjeev, Jain, Thilo, Jakob, Ruth Cerino, Javier, Antonio, João, Luiza Marek, Jozefowicz, Chang-Gyu, Jung, Martin, Kaatz, Nida, Kacar, Henry, Kanarek, Iva, Karlova, Alexander, Kastanayan, Jana, Kazandjieva, Johannes, Kern, Aharon, Kessel, Neena, Khanna, HeeJoo, Kim, Nancy, Kim, Sang-Ha, Kim, Tae-bum, Kim, Kulli, Kingo, Andreas, Kleinheinz, Janka, Komova, Evangelia, Kompoti, Tomas, Kopal, Peter, Kozub, Dorota, Krasowska, Beata, Krecisz, Burkhard, Kreft, Satsuki, Kubota, Hitoshi, Kudo, Teja, Kulkarni, Kanokvalai, Kulthanan, Akihiro, Kume, Maciej, Kupczyk, Edward, Lain, Bobby, Lanier, Hilde, Lapeere, Griselle Ortiz, Lasanta, Svetlana, Lazareva, Laura, Lazzeri, Dennis, Ledford, Donghun, Lee, Haur Yueh, Lee, Jeffrey, Leflein, Nicolas, Leitz, Nancy, Levin, Hermenio, Lima, Undine, Lippert, Brian, Lipson, Paula, Luna, Gabriel, Magarinos, Satyaprakash, Mahajan, Michail, Makris, Alejandro, Malbran, Ahmed Manjra, Manjra, Michael, Manning, Maria, Manrique, Adriana, Marcipar, Mariano, Marini, Veronique Del, Marmol, Jorge, Maspero, Tomoko, Matsuda, Jonathan, Matz, Marcus, Maurer, Wendy, McFalda, Anne, Mclaughlin, Iris, Medina, Rajesh Dutt, Mehta, Stephan, Meller, Steven, MELTZER, Raisa, Meshkova, Dorin, Mihalache, Francisco Javier, Miquel, Mourad, Mokni, J, Molhoek, Efrain, Montano, Sabine, Mueller, Javier Pedraz, Munoz, Toshikazu, Nagakura, Joanna, Narbutt, Ignasi Figueras, Nart, Ma. Lourdes M, Nebrida-Idea, Trong Hao, Nguyen, Johannes, Niesmann, Violeta Zaragoza, Ninet, Hiromitsu, Noguchi, Yuko Chinuki, Nomura, Roman, Nowicki, Tokuya, Omi, Robert, Onder, Ivan, Orojan, Francisco Javier, Ortiz de Frutos, Kim, Papp, Claudio, Parisi, Chun Wook, Park, Heungwoo, Park, Jungwon, Park, Young Min, Park, Viviana, Parra, Thierry, Passeron, Justine, Pasteur, Shivakumar, Patil, Vergil, Patrascu, Sylvia, Pauser, Anna Wojas, Pelc, Jonathan Grant, Peter, Wolfgang, Pfuetzner, Nicola, Pimpinelli, Andreas, Pinter, Cristian, Pizarro, Karel, Pizinger, Jarmila, Plutinska, Todor, Popov, Veronika, Popova, Marta Ferrer, Puga, Lara Ferrandiz, Pulido, Anca, Purcaru, Ulrike, Raap, Anna, Rajchel, John, Ramey, Ma Deanna Santos, Ramiscal, German Dario, Ramon, Syed, Rehman, Adam, Reich, Norbert, Reider, Krista, Ress, Dimitrios, Rigopoulos, Enrique, Rivas, Heike, Rockmann, Pierre-Paul, Roquet-Gravy, Menachem, Rottem, Vermen Verallo, Rowell, Franziska, Rueff, Juan Alberto Ruano, Ruiz, Juan, Russo, Ronald, Saff, Sarbjit, Saini, Maria, Salazar, Juan Francisco Silvestre, Salvador, Jorge, Sanchez, Florica, Sandru, Mark, Scarupa, Knut, Schaekel, Sibylle, Schliemann, Rik, Schrijvers, Beate, Schwarz, Andreas, Schwinn, Sudhir, Sekhsaria, Nilgun, Senturk, Seong Jun, Seo, Mercedes Rodriguez, Serna, Faradiba, Serpa, Paul A, Shapero, Eriko, Shinkawa, Jan-Christoph, Simon, Rodney, Sinclair, Ralfi, Singer, Dareen D, Siri, Karl, Sitz, Adam, Smialowski, Andrew, Smith, Morten, Soerensen, Wiebke, Sondermann, Haejun, Song, Dmitrii, Sonin, Weily, Soong, Daniel, Soteres, Maria, Staevska-Kotasheva, Petra, Staubach-Renz, Nisha Su Yien, Subash, Gordon, Sussman, Ake Svensson, Svensson, Ekaterini, Syrigou, Andrea, Szegedi, Jacek, Szepietowski, Shunsuke, Takahagi, Yuval, Tal, Neetu, Talreja, Wooi Chiang, Tan, Ricardo, Tan, Jyh Jong, Tang, Tonny, Tanus, Martha, Tarpay, Shang Ian, Tee, Craig, Teller, Florence, Tetart, Aurelie Du, Thanh, Suganthi, Thevarajah, Simon Francis, Thomsen, Carl, Thornblade, Milan, Tjioe, Alberto, Tolcachier, Celeste, Tolentino, Athanasios, Tsianakas, Ilia, Tsingov, Hamida, Turki, Olga, Ukhanova, Jens, Ulrich, Meltem, Uslu, Fernando, Valenzuela, Solange, Valle, Martijn, van Doorn, Jirina, Vankova, Suneel, Vartak, Christine, Vidouria, Sebastian, Volc, Gerald, Volcheck, Nicola, Wagner, Irena, Walecka-Herniczek, Penpun, Wattanakrai, Bettina, Wedi, Steven, Weinstein, Vesarat, Wessagowit, Hugh, Windom, Akiko, Yagami, Aisaku, Yamamoto, Shinichiro, Yasumoto, Young Min, Ye, Jose Cevallos, Yepez, Sang Woong, Youn, Hana, Zelenkova, Oleg, Ziganshin, Matthew, Zook, Maurer, Marcus, Ensina, Luis Felipe, Gimenez-Arnau, Ana Maria, Sussman, Gordon, Hide, Michihiro, Saini, Sarbjit, Grattan, Clive, Fomina, Daria, Rigopoulos, Dimitrios, Berard, Frederic, Canonica, Giorgio Walter, Rockmann, Heike, Szepietowski, Jacek C, Leflein, Jeffrey, Bernstein, Jonathan A, Peter, Jonny G, Kulthanan, Kanokvalai, Godse, Kiran, Ardusso, Ledit, Ukhanova, Olga, Staubach, Petra, Sinclair, Rodney, Gogate, Shaila, Thomsen, Simon Francis, Tanus, Tonny, Ye, Young Min, Burciu, Alis, Barve, Avantika, Modi, Darshna, Scosyrev, Emil, Hua, Eva, Letzelter, Kerstin, Varanasi, Vineeth, Patekar, Manmath, and Severin, Thomas
- Published
- 2024
- Full Text
- View/download PDF
8. COVAX – Time to reconsider the strategy and its target
- Author
-
David Bell, Garrett W. Brown, Wellington A. Oyibo, Samiratou Ouédraogo, Blagovesta Tacheva, Elena Barbaud, Andreas Kalk, Valéry Ridde, and Elisabeth Paul
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
COVAX, the international initiative supporting COVID-19 vaccination campaigns globally, is budgeted to be the costliest public health initiative in low- and middle-income countries, with over 16 billion US dollars already committed. While some claim that the target of vaccinating 70% of people worldwide is justified on equity grounds, we argue that this rationale is wrong for two reasons. First, mass COVID-19 vaccination campaigns do not meet standard public health requirements for clear expected benefit, based on costs, disease burden and intervention effectiveness. Second, it constitutes a diversion of resources from more cost-effective and impactful public health programmes, thus reducing health equity. We conclude that the COVAX initiative warrants urgent review.
- Published
- 2023
- Full Text
- View/download PDF
9. Assessing delayed penicillin hypersensitivity using the PENFAST+ score
- Author
-
Julie Castagna, François Chasset, Jean-Eric Autegarden, Claire Le Thai, Emmanuelle Amsler, Annick Barbaud, and Angèle Soria
- Subjects
penicillin allergy ,diagnostic score ,drug hypersensitivity ,delayed hypersensitivity ,PEN-FAST clinical decision rule ,delabelling ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionApproximately 10% of individuals report a suspected allergy to penicillin, but according to allergy work-ups, only 10%–15% of them are truly allergic. A clinical decision score, the PEN-FAST, was developed and validated to identify adults with low-risk penicillin allergy.ObjectivesThe objective of this study was to improve the performance of the PEN-FAST score, particularly for those with delayed hypersensitivity (HS), by improving the negative predictive value.MethodsSTEP 1: Retrospective evaluation of the PEN-FAST score in patients with proven immediate and delayed penicillin allergy. STEP 2: Identification of additional criteria among Step 1 patients misclassified by PEN-FAST score. Development of the PEN-FAST+ score using multivariable logistic regression in a prospective cohort of patients with a suspicion of HS to penicillin. STEP 3: Comparison of diagnostic performances of PEN-FAST and PEN-FAST+ scores.ResultsThe PEN-FAST score showed limitations in predicting the relapse of immediate skin HS or delayed maculopapular exanthema, with 28.6% and 38.4% of patients misclassified, respectively. We identified two potential additional criteria: skin rash lasting more than 7 days and immediate reaction occurring in less than 1 h (generalized or localized on palmoplantar area or scalp itching/heat feeling). A total of 32/252 (12.7%) patients were confirmed to be allergic to penicillin. With PEN-FAST, 37% of patients (n = 10) with delayed allergic penicillin HS were misclassified. With PEN-FAST+, 3 patients with delayed HS confirmed by a ST (11.1%) were misclassified. The AUC was significantly higher for PEN-FAST+ than PEN-FAST (85% vs. 72%, p = 0.03).
- Published
- 2023
- Full Text
- View/download PDF
10. COVAX – Time to reconsider the strategy and its target
- Author
-
Bell, David, Brown, Garrett W., Oyibo, Wellington A., Ouédraogo, Samiratou, Tacheva, Blagovesta, Barbaud, Elena, Kalk, Andreas, Ridde, Valéry, and Paul, Elisabeth
- Published
- 2023
- Full Text
- View/download PDF
11. Swiss Official Gazette of Commerce notice: RC of the canton of Vaud: New entries Technical service Barbaud, Mies HR01-1004577382
- Subjects
Consultants (Persons) ,Housing ,Building permits ,General interest ,News, opinion and commentary - Abstract
Bern: Swiss Official Gazette of Commerce has issued the following notice: New entries Technical service Barbaud, Mies Technical service BarbaudRoute du Village 37 1295 Mies Legal form: Individually owned company [...]
- Published
- 2019
12. “SCULP” study: The benefits of skin graft pellets on the pain of sickle cell leg ulcers (SCLU)
- Author
-
Caboche-Salouhi, P., Le Seac’h, A., Lionnet, F., Santin, A., Mattioni, S., Tamboura, F., Steichen, O., Barbaud, A., and Senet, P.
- Published
- 2023
- Full Text
- View/download PDF
13. GW501516-Mediated Targeting of Tetraspanin 15 Regulates ADAM10-Dependent N-Cadherin Cleavage in Invasive Bladder Cancer Cells
- Author
-
Alexandre Barbaud, Isabelle Lascombe, Adeline Péchery, Sergen Arslan, François Kleinclauss, and Sylvie Fauconnet
- Subjects
bladder cancer ,N-cadherin ,ADAM10 ,tetraspanin 15 ,PPARβ/δ ,GW501516 ,Cytology ,QH573-671 - Abstract
Bladder cancer aggressiveness is correlated with abnormal N-cadherin transmembrane glycoprotein expression. This protein is cleaved by the metalloprotease ADAM10 and the γ-secretase complex releasing a pro-angiogenic N-terminal fragment (NTF) and a proliferation-activating soluble C-terminal fragment (CTF2). Tetraspanin 15 (Tspan15) is identified as an ADAM10-interacting protein to induce selective N-cadherin cleavage. We first demonstrated, in invasive T24 bladder cancer cells, that N-cadherin was cleaved by ADAM10 generating NTF in the extracellular environment and leaving a membrane-anchored CTF1 fragment and that Tspan15 is required for ADAM10 to induce the selective N-cadherin cleavage. Targeting N-cadherin function in cancer is relevant to preventing tumor progression and metastases. For antitumor molecules to inhibit N-cadherin function, they should be complete and not cleaved. We first showed that the GW501516, an agonist of the nuclear receptor PPARβ/δ, decreased Tspan15 and prevented N-cadherin cleavage thus decreasing NTF. Interestingly, the drug did not modify ADAM10 expression, which was important because it could limit side effects since ADAM10 cleaves numerous substrates. By targeting Tspan15 to block ADAM10 activity on N-cadherin, GW501516 could prevent NTF pro-tumoral effects and be a promising molecule to treat bladder cancer. More interestingly, it could optimize the effects of the N-cadherin antagonists those such as ADH-1 that target the N-cadherin ectodomain.
- Published
- 2024
- Full Text
- View/download PDF
14. Acute generalized exanthematous pustulosis: European expert consensus for diagnosis and management.
- Author
-
Tetart F, Walsh S, Milpied B, Gaspar K, Vorobyev A, Tiplica GS, Didona B, Welfringer-Morin A, Kucinskiene V, Bensaid B, Marvanova E, Salavastru C, Brezinova E, Chua SL, Lovgren ML, Hammers CM, Barbaud A, Mortz CG, Horvath B, Meyersburg D, Lebrun-Vignes B, Bodemer C, Brüggen MC, French LE, and Ingen-Housz-Oro S
- Abstract
Acute generalized exanthematous pustulosis (AGEP) is a rare, usually drug-induced, acute pustular rash. Despite the lack of strong data supporting the effectiveness of topical or systemic corticosteroids in this drug reaction, they are widely used. More generally, there is no consensus on the diagnostic modalities and the management of patients with AGEP. We aimed to provide European expert recommendations for the diagnosis and management or patients with AGEP. Members of the ToxiTEN group of the European Reference Network (ERN)-skin, all dermatologists and/or allergologists with expertise in drug reactions, elaborated these recommendations based on their own experience and on a review of the literature. Recommendations were separated into the following categories: professionals involved, assessment of the diagnosis of AGEP, management of the patient and allergological work-up after the acute phase. Consensus was obtained among experts for the list of professionals involved for the diagnosis and management of AGEP, including the minimum diagnostic work-up, the setting of management, the treatments, the modalities and the timing of allergological work-up and follow-up. European experts in drug allergies propose herein consensus on the diagnosis and management of patients with AGEP. A multidisciplinary approach is warranted, including dermatologists, allergologists and pharmacovigilance services., (© 2024 The Author(s). Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)
- Published
- 2024
- Full Text
- View/download PDF
15. Novelty in the development of biodegradable polymer coatings for biomedical devices: paclitaxel grafting on PDMMLA derivatives
- Author
-
Elnaz Gholizadeh, Meriem Naim, Rima Belibel, Hanna Hlawaty, and Christel Barbaud
- Subjects
pdmmla ,polyesters ,paclitaxel ,covalent grafting ,steglich esterification ,drug eluting polymers ,Polymers and polymer manufacture ,TP1080-1185 - Abstract
Biocompatible and biodegradable polymers are widely used in the medical field. In some cases, the biopolymer is accompanied by an active drug, which is delivered locally in a controlled manner in order to improve the healing conditions. Poly([R,S]-3,3-dimethylmalic acid) (PDMMLA) is a synthetic amphiphilic biodegradable polymer, which unlike PLA, can be chemically modified to adapt hydrophilic/hydrophobic balance, degradation kinetics, and physicochemical and biological properties. It may contain a lateral alkyl group or a functional group for coupling bioactive molecules to release during its degradation. In this work, we realized the chemical grafting of paclitaxel (PTX), a microtubule stabilizing anti-cancer agent on PDMMLA derivatives bio-polyesters following a Steglich esterification protocol. 1D and 2D NMR analyses validated the reaction with 10% (using 0.1 equivalent) of PTX on the copolymer PDMMLAH40-co-Hex60 (PDMMLA 40/60) and a maximal PTX grafting rate of 55% on the homopolymer PDMMLAH (PDMMLA 100/0). In vitro adhesion and cytotoxicity assays were carried out on HUVEC cells with PDMMLA 40/60, PDMMLA-PTX 30/10/60 and PLA.
- Published
- 2022
- Full Text
- View/download PDF
16. Pierre Barbaud: 1911-1990
- Published
- 1992
17. Stable tin perovskite solar cells developed via additive engineering
- Author
-
Dai, Zhensheng, Lv, Taoyuze, Barbaud, Julien, Tang, Wentao, Wang, Tao, Qiao, Liang, Chen, Han, Zheng, Rongkun, Yang, Xudong, and Han, Liyuan
- Published
- 2021
- Full Text
- View/download PDF
18. Skin Testing and Drug Provocation Tests in Epidermal Necrolysis: A French Experience
- Author
-
Roux, Camille, Ben Said, Benoit, Milpied, Brigitte, Bernier, Claire, Staumont-Sallé, Delphine, Dezoteux, Frédéric, Soria, Angèle, Barbaud, Annick, Valeyrie-Allanore, Laurence, Tétart, Florence, Bellon, Nathalia, Lebrun-Vignes, Bénédicte, Gener, Gwendeline, Paul, Muriel, Ingen-Housz-Oro, Saskia, and Assier, Haudrey
- Published
- 2022
- Full Text
- View/download PDF
19. Performance accuracy, advantages and limitations of a store-and-forward teledermatology platform developed for general practitioners: A retrospective study of 298 cases
- Author
-
Faucon, C., Gribi, D., Courvoisier, D.S., Senet, P., Itani, O., Barbaud, A., Magnier, A.-M., Frances, C., Chastang, J., and Chasset, F.
- Published
- 2022
- Full Text
- View/download PDF
20. Hypersensitivity reactions to proton pump inhibitors. An EAACI position paper.
- Author
-
Bavbek S, Kepil Özdemir S, Bonadonna P, Atanaskovic-Markovic M, Barbaud A, Brockow K, Laguna Martinez J, Nakonechna A, Pagani M, Arcolacı A, Lombardo C, and Torres MJ
- Subjects
- Humans, Proton Pump Inhibitors adverse effects, Skin Tests, Drug Hypersensitivity diagnosis, Drug Hypersensitivity etiology, Drug Hypersensitivity therapy, Hypersensitivity, Hypersensitivity, Immediate diagnosis
- Abstract
Proton pump inhibitors (PPIs) are invaluable therapeutic options in a variety of dyspeptic diseases. In addition to their well-known risk profile, PPI consumption is related to food and environmental allergies, dysbiosis, osteoporosis, as well as immediate and delayed hypersensitivity reactions (HSRs). The latter, although a rare event, around 1%-3%, due to the extraordinarily high rate of prescription and consumption of PPIs are related to a substantial risk. In this Position Paper, we provide clinicians with practical evidence-based recommendations for the diagnosis and management of HSRs to PPIs. Furthermore, the unmet needs proposed in the document aim to stimulate more in-depth investigations in the topic., (© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
21. EAACI/ENDA position paper on drug provocation testing.
- Author
-
Barbaud A, Garvey LH, Torres M, Laguna JJ, Arcolaci A, Bonadonna P, Scherer Hofmeier K, Chiriac AM, Cernadas J, Caubet JC, and Brockow K
- Subjects
- Child, Adult, Humans, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Contrast Media, Monobactams, beta Lactam Antibiotics, Skin Tests methods, Anti-Bacterial Agents adverse effects, Drug Hypersensitivity diagnosis
- Abstract
In drug hypersensitivity, drug provocation testing (DPT), also called drug challenge, is the gold standard for investigation. In recent years, risk stratification has become an important tool for adjusting the diagnostic strategy to the perceived risk, whilst still maintaining a high level of safety for the patient. Skin tests are recommended before DPT but may be omitted in low-risk patients. The task force suggests a strict definition of such low-risk patients in children and adults. Based on experience and evidence from studies of allergy to beta-lactam antibiotics, an algorithm on how to adjust DPT to the risk, and when to omit skin tests before DPT, is presented. For other antibiotics, non-steroidal anti-inflammatory drugs and other drugs, skin tests are poorly validated and DPT is frequently necessary. We recommend performing DPT with chemotherapeutics and biologicals to avoid unnecessary desensitization procedures and DPT with skin tests negative contrast media. We suggest DPT with anesthetics only in highly specialized centers. Specifics of DPT to proton pump inhibitors, anticonvulsants and corticosteroids are discussed. This position paper provides general recommendations and guidance on optimizing use of DPT, whilst balancing benefits with patient safety and optimizing the use of the limited available resources., (© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
22. Skin Testing Approaches for Immediate and Delayed Hypersensitivity Reactions
- Author
-
Barbaud, Annick and Romano, Antonino
- Published
- 2022
- Full Text
- View/download PDF
23. Antiphospholipid-negative Sneddon's syndrome: A comprehensive overview of a rare entity
- Author
-
Assan, F., Bottin, L., Francès, C., Moguelet, P., Tavolaro, S., Barbaud, A., de Zuttere, D., Alamowitch, S., and Chasset, F.
- Published
- 2022
- Full Text
- View/download PDF
24. Topical versus oral corticosteroids in moderate drug reaction with eosinophilia and systemic symptoms: A multicenter randomized clinical trial.
- Author
-
Ingen-Housz-Oro, Saskia, Guichard, Elie, Milpied, Brigitte, Bensaid, Benoit, Collet, Evelyne, Barbaud, Annick, Le Duff, Florence, Tétart, Florence, Soria, Angèle, Machet, Laurent, Descamps, Vincent, Monestier, Sandrine, Pasteur, Justine, Morice, Cécile, Chaby, Guillaume, Colin, Audrey, Grégoire, Laëtitia, Allanore, Laurence, Giraudeau, Bruno, and Chosidow, Olivier
- Published
- 2024
- Full Text
- View/download PDF
25. Commentary: Comparison of newer hand-held ultrasound devices for post-dive venous gas emboli quantification to standard echocardiography
- Author
-
Metelkina Asya and Barbaud Axel
- Subjects
decompression sickness ,decompression stress ,diving ,bubble ,Doppler ,Physiology ,QP1-981 - Published
- 2023
- Full Text
- View/download PDF
26. Allergic contact dermatitis from vitamins: A systematic review
- Author
-
Caterina Foti, Gianfranco Calogiuri, Eustachio Nettis, Aurora De Marco, Luca Stingeni, Katharina Hansel, Danilo Di Bona, Palma Carlucci, Paolo Romita, and Annick Barbaud
- Subjects
allergic contact dermatitis ,fat‐soluble vitamins ,hydro‐soluble vitamins ,lymphocyte transformation test ,multivitamins ,patch test ,Medicine - Abstract
Abstract Background and Aims Vitamins are bioactive compounds naturally found in many different types of food and required by the human body for many biological functions and enzymatic activities. Due to their antioxidant properties, certain vitamin derivatives have been synthesized for inclusion in many cosmetics, thus leading to an increasing incidence of allergic contact dermatitis (ACD) cases. Therefore, the present review may be helpful to provide an insight into the sensitizing role of at least certain vitamins and may also offer possible patch test alternatives for definitive diagnosis. Methods This study was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta‐Analyses (PRISMA) guidelines. Literature search regarding ACD cases to vitamins was performed using the Medline, PubMed, Scopus, EMBASE, and Google Scholar databases from January 1940 up to June 2021. Results A total of 4494 articles matched the keywords used for the researched. Records removed before screening included 15 duplicate articles and 3429 not eligible articles (e.g., not written in English, studies on animals, not relevant to the topic). A total of 1050 articles underwent the screening phase and 258 were therefore excluded as they were not primary studies. Subsequentially, 792 articles were considered eligible for the review and 688 of them were finally excluded as they did not report the outcome of interest. Therefore, 104 articles were definitely included in the present review. Conclusion ACD to vitamins is still probably an underestimated issue in cosmetology, as many vitamins are considered “natural” and therefore “safe” ingredients. On the contrary, according to current literature, almost all vitamins contained in topical products are able to induce allergic reactions, with the exception of vitamin B2 and vitamin B9. Patch tests are not standardized, thus leading to difficulties in diagnosis.
- Published
- 2022
- Full Text
- View/download PDF
27. Cutaneous drug-induced lupus erythematosus: Clinical and immunological characteristics and update on new associated drugs
- Author
-
Bataille, P., Chasset, F., Monfort, J.-B., De Risi-Pugliese, T., Soria, A., Francès, C., Barbaud, A., and Senet, P.
- Published
- 2021
- Full Text
- View/download PDF
28. DRESS and AGEP Reactions to Iodinated Contrast Media: A French Case Series
- Author
-
Soria, Angèle, Amsler, Emmanuelle, Bernier, Claire, Milpied, Brigitte, Tétart, Florence, Morice, Cécile, Dezoteux, Frédéric, Ferrier-Le Bouedec, Marie-Christine, Barbaud, Annick, Staumont-Sallé, Delphine, and Assier, Haudrey
- Published
- 2021
- Full Text
- View/download PDF
29. Systemic sclerosis is associated with lower limb vascular stiffness and microvascular impairment: results from a prospective study
- Author
-
Cassius, Charles, Seta, Vannina, Monfort, Jean-Benoit, Baudot, Nathalie Abdoucheli, Rivière, Sébastien, Mekinian, Arsène, Frances, Camille, Barbaud, Annick, and Senet, Patricia
- Published
- 2021
- Full Text
- View/download PDF
30. Discrepancies in the management of acquired cold contact urticaria: Results of a French-speaking urticaria experts questionnaire survey
- Author
-
Aurélie Du-Thanh, MD, PhD, Angèle Soria, MD, PhD, Emmanuelle Amsler, MD, Antoine Badaoui, MD, Marie-Sylvie Doutre, MD, PhD, Germaine Gabison, MD, Claire Bernier, MD, Delphine Staumont-Sallé, MD, PhD, Florence Hacard, MD, Florence Castelain, MD, Anne-Sophie Darrigade, MD, Gilbert Patrice ML Tapsoba, MD, Marie-Elodie Sarre, MD, Pascale Mathelier-Fusade, MD, Juliette Delaunay, MD, Pauline Pralong, MD, Annick Barbaud, MD, PhD, Frédéric Dezoteux, MD, Catherine Trémeau-Martinage, MD, Zhary Bachtarzi, MD, and Frédéric Augey, MD
- Subjects
Acquired cold contact urticaria ,Recommendations ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Acquired cold contact urticaria (ACU) is a putatively serious condition, because of the risk of anaphylactic shock whenever patients are massively exposed to cold atmosphere/water, raising the question of the prescription of an “emergency kit” with oral antihistamines and epinephrine auto-injector. We performed an online survey to evaluate how French-speaking urticaria experts manage ACU. According to the 2016 consensus recommendations on chronic inducible urticarias, all the participants perform at least 1 of the available provocation tests and 84.2%, 77.8%, and 88.9% prescribe on-label use of second generation anti-H1 antihistamines (2GAH1) as a first line treatment, updosed 2GAH1 as a second line treatment, and omalizumab as a third line treatment, respectively. Interestingly, 44.4% of the practitioners always prescribe a continuous background treatment, versus 11.1% prescribing only on-demand therapy. Also, 11.7% of participants always prescribe an epinephrine auto-injector, 70.6% sometimes do, and 17.6% never do. Finally, 89.5% authorize swimming under strict conditions but 36.8% and 68.4% contra-indicate other water sports and occupational cold exposure, respectively.
- Published
- 2022
- Full Text
- View/download PDF
31. Immediate hypersensitivity to COVID-19 vaccines: Focus on biological diagnosis
- Author
-
Pascale Nicaise-Roland, Vanessa Granger, Angèle Soria, Annick Barbaud, Marc Pallardy, Sylvie Chollet-Martin, and Luc de Chaisemartin
- Subjects
COVID-19 vaccine ,anaphylaxis ,basophil activation test ,IgE ,complement ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Soon after the release of the new anti-COVID mRNA vaccines, reports came in from the US and the UK of anaphylactic reactions. Fueled by the necessary caution toward these new vaccine platforms, these reports had a great impact and were largely commented upon in the scientific literature and global media. The current estimated frequency is of 5 cases per million doses. Very little biological data are presented in the literature to support the anaphylaxis diagnosis in these patients in addition to skin tests. Allergic reactions to vaccines are rare and mostly due to vaccine excipient. Therefore, the poly-ethylene-glycol (PEG) present in both mRNA formulation, and already known to be immunogenic, was soon suspected to be the potential culprit. Several hypersensitivity mechanisms to PEG or to other vaccine components can be suspected, even if the classical IgE-dependent anaphylaxis seems to be one of the most plausible candidates. In the early 2022, the international guidelines recommended to perform skin prick tests and basophil activation tests (BAT) in people experiencing allergic reaction to the first dose of COVID-19 vaccine or with a history of PEG allergy. The aim of this review is to discuss the main potential mechanisms of immediate allergy to COVID19 vaccines based on published data, together with the various techniques used to confirm or not sensitization to one component.
- Published
- 2022
- Full Text
- View/download PDF
32. GW501516-Mediated Targeting of Tetraspanin 15 Regulates ADAM10-Dependent N-Cadherin Cleavage in Invasive Bladder Cancer Cells.
- Author
-
Barbaud, Alexandre, Lascombe, Isabelle, Péchery, Adeline, Arslan, Sergen, Kleinclauss, François, and Fauconnet, Sylvie
- Subjects
TETRASPANIN ,BLADDER cancer ,CANCER invasiveness ,CANCER cells ,CADHERINS ,METASTASIS ,PRESENILINS - Abstract
Bladder cancer aggressiveness is correlated with abnormal N-cadherin transmembrane glycoprotein expression. This protein is cleaved by the metalloprotease ADAM10 and the γ-secretase complex releasing a pro-angiogenic N-terminal fragment (NTF) and a proliferation-activating soluble C-terminal fragment (CTF2). Tetraspanin 15 (Tspan15) is identified as an ADAM10-interacting protein to induce selective N-cadherin cleavage. We first demonstrated, in invasive T24 bladder cancer cells, that N-cadherin was cleaved by ADAM10 generating NTF in the extracellular environment and leaving a membrane-anchored CTF1 fragment and that Tspan15 is required for ADAM10 to induce the selective N-cadherin cleavage. Targeting N-cadherin function in cancer is relevant to preventing tumor progression and metastases. For antitumor molecules to inhibit N-cadherin function, they should be complete and not cleaved. We first showed that the GW501516, an agonist of the nuclear receptor PPARβ/δ, decreased Tspan15 and prevented N-cadherin cleavage thus decreasing NTF. Interestingly, the drug did not modify ADAM10 expression, which was important because it could limit side effects since ADAM10 cleaves numerous substrates. By targeting Tspan15 to block ADAM10 activity on N-cadherin, GW501516 could prevent NTF pro-tumoral effects and be a promising molecule to treat bladder cancer. More interestingly, it could optimize the effects of the N-cadherin antagonists those such as ADH-1 that target the N-cadherin ectodomain. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Evaluation of North Sea saturation procedures through divers monitoring.
- Author
-
Imbert, Jean-Pierre, Barbaud, Axel, Stevens, Sian, Miller, Craig, Peace, Hilary, Rossin, Helene, Letourneur, Alain, Bryson, Phil, Bo Damsgaard, and Balestra, Costantino
- Published
- 2024
- Full Text
- View/download PDF
34. Risks associated with cosmetic ingredients
- Author
-
Barbaud, A. and Lafforgue, C.
- Published
- 2021
- Full Text
- View/download PDF
35. Allergy Prevalence in France and Skin Impact – Epidemiological Survey of a Representative Sample of French Adults
- Author
-
Seité S, Taieb C, Pham-Thi N, and Barbaud A
- Subjects
allergies ,food allergy ,skin allergy ,respiratory allergy ,prevalence ,skin side effects ,Dermatology ,RL1-803 - Abstract
Sophie Seité,1 Charles Taieb,2 Nhân Pham-Thi,3,4 Annick Barbaud5,6 1La Roche-Posay Dermatological Laboratories, Levallois-Perret, France; 2European Market Maintenance Assessment, Fontenay-sous-Bois, France; 3Ecole Polytechnique, Economics, Palaiseau, France; 4Institut Pasteur Paris, Allergology, Paris, France; 5Dermatology and Allergy Department, Tenon Hospital, Medicine Sorbonne University, Paris, France; 6Assistance Publique-Hôpitaux de Paris, Paris, FranceCorrespondence: Sophie SeitéLa Roche-Posay Dermatological Laboratories, 62 Quai Charles Pasqua, Levallois-Perret, 92300, FranceTel +33 1 49 64 33 40Email sophie.seite@loreal.comBackground: Increased allergy frequency may have a significant impact on the skin, one of the largest targeted organs for allergic and immunological responses.Methods: An online survey of 2036 adults as a representative sample of the French general population was conducted to evaluate the prevalence of self-reported allergies, the populations who report allergies and the skin conditions related to allergies.Results: In general, 20.2% of French adults (average age 45 ± 15.8 years) reported allergies. These allergies were respiratory allergies (55.3%), skin allergies (48.8%) and food allergies (27.9%), and 78.9% indicated that their reported allergies were diagnosed by a doctor. In addition, 53.2% of individuals reporting an allergy also indicated that they experienced associated skin reactions. In comparison to those who did not report an allergy, these individuals were 1.5 to 4 times more likely to have a skin disease and 3 times more likely to have sensitive skin or skin reactions when using skincare products.Conclusion: It is estimated that over 10 million French adults have allergies. These data will help increase awareness among the allergic population and healthcare professionals about the burden associated with allergies and the need for management to reduce their health impact.Keywords: allergies, food allergy, skin allergy, respiratory allergy, prevalence, skin side effects
- Published
- 2021
36. Linear Immunoglobulin a Bullous Dermatosis in Children
- Author
-
Francesca Mori, Francesca Saretta, Lucia Liotti, Mattia Giovannini, Riccardo Castagnoli, Stefania Arasi, Simona Barni, Carla Mastrorilli, Luca Pecoraro, Lucia Caminiti, Gian Luigi Marseglia, Annick Barbaud, and Elio Novembre
- Subjects
linear IgA bullous dermatosis (LABD) ,newborn ,children ,drug hypersensitivity ,epidemiology ,diagnosis ,Pediatrics ,RJ1-570 - Abstract
Linear Immunoglobulin A Bullous Disease (LABD) is a rare dermatosis whose pathomechanisms are not yet completely understood. LABD has different features characterizing adults and children in terms of potential triggers, clinical manifestations, and prognosis. The aim of the present study is to review all neonatal and pediatric cases of LABD and summarize the major characteristics. Childhood LABD is mainly idiopathic with a benign prognosis. Neonatal cases are difficult to differentiate from infectious diseases and usually have a poor prognosis. Drugs are one of the possible triggers that can activate autoimmune responses through antigen mimicry and epitope spreading as well as different stimuli (e.g., infections, inflammatory diseases, trauma). The gold standard for the diagnosis is based on direct immunofluorescence. Prognosis is generally favorable but often depends on the prompt dermatological diagnosis, treatment and follow-up guaranteed by a multidisciplinary team, including pediatricians for this group of age.
- Published
- 2022
- Full Text
- View/download PDF
37. Paradoxical urticaria to H1-antihistamines.
- Author
-
Soria A, Kurihara F, Amsler E, Bréhon A, Autegarden JE, and Barbaud A
- Published
- 2024
- Full Text
- View/download PDF
38. Doxycycline-induced fixed drug eruption: The new epidemic?
- Author
-
Brehon A, Lourenco J, Badaoui A, Amsler E, Lopez Zaragoza JL, Soria A, and Barbaud A
- Published
- 2024
- Full Text
- View/download PDF
39. Risk stratification through extensive allergy work‐up in COVID‐19‐mRNA vaccine allergic reactions.
- Author
-
Soria, Angèle, Labella, Marina, Doña, Inmaculada, Nicaise‐Roland, Pascale, Chollet‐Martin, Sylvie, Autegarden, Jean‐Eric, Castagna, Julie, Le Thai, Claire, de Chaisemartin, Luc, Torres, Maria José, and Barbaud, Annick
- Subjects
ALLERGIES ,VACCINES ,ANAPHYLAXIS ,SKIN tests ,POLYETHYLENE glycol - Abstract
In 145 patients, revaccination was performed with the culprit vaccine, which was well tolerated in 126 of the patients, and 15 of the patients had an alternative COVID-19 vaccine (other mRNA vaccine for 12), which was well tolerated in 13 of the patients (Figure 1). Keywords: allergy; anaphylaxis; COVID-19-mRNA vaccines EN allergy anaphylaxis COVID-19-mRNA vaccines 2320 2323 4 08/02/23 20230801 NES 230801 To the Editor, The mechanisms of allergic reactions to COVID-19-mRNA vaccines have not been elucidated. One hundred and sixty patients (84%) were revaccinated (122 under antihistamine premedication), 139 patients (87%) had good tolerance, and 30 patients refused further COVID-19 vaccination. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
40. PDMMLA derivatives as a promising cardiovascular metallic stent coating: Physicochemical and biological evaluation
- Author
-
Belibel, R., Sali, S., Marinval, N., Garcia-Sanchez, A., Barbaud, C., and Hlawaty, H.
- Published
- 2020
- Full Text
- View/download PDF
41. Surface-Controlled Oriented Growth of FASnI3 Crystals for Efficient Lead-free Perovskite Solar Cells
- Author
-
Meng, Xiangyue, Wang, Yanbo, Lin, Jianbo, Liu, Xiao, He, Xin, Barbaud, Julien, Wu, Tianhao, Noda, Takeshi, Yang, Xudong, and Han, Liyuan
- Published
- 2020
- Full Text
- View/download PDF
42. Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper.
- Author
-
Mayorga C, Çelik GE, Pascal M, Hoffmann HJ, Eberlein B, Torres MJ, Brockow K, Garvey LH, Barbaud A, Madrigal-Burgaleta R, Caubet JC, and Ebo DG
- Subjects
- Humans, Child, Basophil Degranulation Test methods, Basophils, COVID-19 Vaccines, Hypersensitivity, Immediate, Drug Hypersensitivity diagnosis, Hypersensitivity
- Abstract
Diagnosing immediate drug hypersensitivity reactions (IDHRs) can pose a significant challenge and there is an urgent need for safe and reliable tests. Evidence has emerged that the basophil activation test (BAT), an in vitro assay that mirrors the in vivo response, can be a complementary test for many drugs. In this position paper, members of Task Force (TF) "Basophil activation test in the evaluation of Drug Hypersensitivity Reactions" from the European Academy of Allergy and Clinical Immunology (EAACI) present the data from a survey about the use and utility of BAT in IDHRs in Europe. The survey results indicate that there is a great interest for using BAT especially for diagnosing IDHRs. However, there are still main needs, mainly in the standardization of the protocols. Subsequently consensus-based recommendations were formulated for: (i) Technical aspects of BAT in IDHRs including type of sample, management of drugs, flow cytometry protocols, interpretation of the results; and (ii) Drug-specific aspects that should be taken into account when performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhexidine, opioids, radio contrast media, chemotherapeutics, biological agents, nonsteroidal anti-inflammatory drugs, COVID vaccine, and excipients. Moreover, aspects in the evaluation of pediatric population have also been considered. All this indicates that BAT offers the clinician and laboratory a complementary tool for a safe diagnostic for IDHRs, although its place in the diagnostic algorithm depends on the drug class and patient population (phenotype, geography, and age). The standardization of BAT is important for generalizing this method beyond the individual laboratory., (© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
43. Efficient and stable tin perovskite solar cells enabled by amorphous-polycrystalline structure
- Author
-
Xiao Liu, Yanbo Wang, Tianhao Wu, Xin He, Xiangyue Meng, Julien Barbaud, Han Chen, Hiroshi Segawa, Xudong Yang, and Liyuan Han
- Subjects
Science - Abstract
Tin based perovskite solar cells could be promising replacements for lead based counterparts due to their lower toxicity, but their efficiencies are much lower. Here, Liu et al. report stable tin based perovskite solar cells with efficiency over 10% by designing amorphous-polycrystalline nanostructures.
- Published
- 2020
- Full Text
- View/download PDF
44. Efficient Perovskite Solar Cell Modules with High Stability Enabled by Iodide Diffusion Barriers
- Author
-
Bi, Enbing, Tang, Wentao, Chen, Han, Wang, Yanbo, Barbaud, Julien, Wu, Tianhao, Kong, Weiyu, Tu, Peng, Zhu, Hong, Zeng, Xiaoqin, He, Jinjin, Kan, Shin-ichi, Yang, Xudong, Grätzel, Michael, and Han, Liyuan
- Published
- 2019
- Full Text
- View/download PDF
45. Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus.
- Author
-
Brüggen, Marie-Charlotte, Walsh, Sarah, Ameri, M. Milad, Anasiewicz, Natalie, Maverakis, Emanual, French, Lars E., Ingen-Housz-Oro, Saskia, Abe, Richiiro, Ardern-Jones, Michael, Assier, Haudrey, Barbaud, Annick, Bensaid, Benoit, Bernal, William, Bernier, Claire, Brassard, Alain, Březinová, Eva, Cabañas, Rosario, Cardones, Adela, Chu, Chia-Yu, and Chua, Ser-Ling
- Published
- 2024
- Full Text
- View/download PDF
46. New Dermatology Findings Has Been Reported by A. Barbaud et al (Occupational protein contact dermatitis)
- Subjects
Contact dermatitis -- Research ,Health - Abstract
2016 MAR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Researchers detail new data in Health and Medicine. According to news reporting originating [...]
- Published
- 2016
47. Controversies in drug allergy: Testing for delayed reactions
- Author
-
Phillips, Elizabeth J., Bigliardi, Paul, Bircher, Andreas J., Broyles, Ana, Chang, Yoon-Seok, Chung, Wen-Hung, Lehloenya, Rannakoe, Mockenhaupt, Maja, Peter, Jonny, Pirmohamed, Munir, Roujeau, Jean-Claude, Shear, Neil H., Tanno, Luciana Kase, Trubiano, Jason, Valluzzi, Rocco, and Barbaud, Annick
- Published
- 2019
- Full Text
- View/download PDF
48. Administration of an alternative iodinated contrast media in confirmed severe delayed hypersensitivity reactions.
- Author
-
Soria A, Bernier C, Milpied B, Assier H, Castelain F, Amsler E, and Barbaud A
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Skin Tests, Contrast Media adverse effects, Drug Hypersensitivity diagnosis, Hypersensitivity, Delayed diagnosis
- Published
- 2024
- Full Text
- View/download PDF
49. Management of anaphylaxis due to COVID-19 vaccines in the elderly
- Author
-
Paulo Augusto Moreira Camargos, Radolslaw Gawlik, Mirko Petrovic, Gunter J. Sturm, Kristof Nekam, Sergio Bonini, Zhanat Ispayeva, Marilyn Urrutia Pereira, Jean Bousquet, Antti Lauerma, Menachem Rottem, Arzu Yorgancioglu, Hubert Blain, Antonio Cherubini, Mário Morais-Almeida, Nathalie Salles, Charlotte G. Mortz, Sylwia Smolinska, Davor Plavec, A. Bedbrook, Torsten Zuberbier, Helga Kraxner, M. Beatrice Bilò, Sinthia Bosnic-Anticevich, Gaëtan Gavazzi, Finbarr C. Martin, Alvaro A. Cruz, K. S. Bennoor, Isabella Annesi-Maesano, Mohamed H. Shamji, Karin Hoffmann-Sommergruber, Marina Atanaskovic-Markovic, Carsten Bindslev-Jensen, Lan Tt Le, Isabel Skypala, Ana Todo-Bom, Vincenzo Patella, Lorenzo Cecchi, Charlotte Suppli Ulrik, Oscar Palomares, Joaquin Sastre, Hans Jürgen Hoffmann, Knut Brockow, Eva Untersmayr, Martin Hrubisko, Bernadette Eberlein, Aziz Sheikh, Milan Sova, Osman M. Yusuf, Violeta Kvedariene, G. Walter Canonica, Dana Wallace, Ioana Agache, Milena Sokolowska, Jos M. G. A. Schols, Susan Waserman, Stéphanie Miot, Carla Irani, Regina E Roller-Winsberger, Michael Levin, Yves Rolland, Emma Montella, Bilun Gemicioglu, Bolesław Samoliński, Stefano Del Giacco, Madda lenaIllario, Yehia El-Gamal, Olga Lourenço, Jean-Christoph Roger J-P Caubet, Luisa Brussino, Marysia Recto, De Yun Wang, Igor Kaidashev, Renaud Louis, Antonino Romano, Mario E. Zernotti, Jacques Reynes, Pedro Carreiro-Martins, Alexandra F. Santos, Marek Niedoszytko, M. Gotua, Musa Khaitov, Thomas B. Casale, Andrea Matucci, Bernardo Sousa-Pinto, Rafael Stelmach, Dejan Dokic, Joana Vitte, Motohiro Ebisawa, Maria Teresa Ventura, Joaquim Mullol, Tomas Chivato, Petr Panzner, Oliver Pfaar, Sanna Toppila-Salmi, Ioanna Tsiligianni, Wytske Fokkens, Alessandra Vultaggio, H. Neffen, Juan Carlos Ivancevich, Ya-dong Gao, Anna Sediva, Maja Hofmann, Ana Maria Carriazo, João Fonseca, Marek Jutel, A. Benetos, Nhân Pham-Thi, Mona Al-Ahmad, Arunas Valiulis, Mihaela Zidarn, Elizabeth Angier, Yoshitaka Okamoto, Montserrat Fernandez-Rivas, Cezmi A. Akdis, Philip W. Rouadi, Olivier Guérin, John Farrell, Mikaela Odemyr, George Christoff, Vera Mahler, Claus Bachert, Edward F. Knol, Wienczyslawa Czarlewski, Robyn E O'Hehir, Victoria Cardona, Ludger Klimek, Tari Haahtela, Vincent Le Moing, Branislava Milenkovic, Carmen Rondon, Kaja Julge, Jolanta Walusiak-Skorupa, Nikolaos G. Papadopoulos, Aslı Gelincik, Markus Ollert, Piotr Kuna, Leyla Namazova-Baranova, Margitta Worm, Annick Barbaud, Elena Camelia Berghea, Todor A. Popov, Derek K. Chu, María José Torres, Faradiba Sarquis Serpa, Nicola Scichilone, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Gianni Passalacqua, Humboldt-Universität zu Berlin, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Humboldt University Of Berlin, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Transylvania University, Wrocław Medical University, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Cagliari, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Università Politecnica delle Marche [Ancona] (UNIVPM), Medical Consulting Czarlewski, Universiti Putra Malaysia, University of Southampton, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Belgrade [Belgrade], Ghent University Hospital, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Dhaka Shishu Hospital [Bangladesh], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Odense University Hospital (OUH), Italian National Research Council, National Research Council [Italy] (CNR), The University of Sydney, Technische Universität München = Technical University of Munich (TUM), Università degli studi di Torino = University of Turin (UNITO), Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), IRCCS Research Hospital, Milan, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, University of South Florida [Tampa] (USF), Geneva University Hospital (HUG), Azienda Usl Toscana centro [Firenze], Софийски университет = Sofia University, McMaster University [Hamilton, Ontario], State University of Bahia, Institute of Public Health of Republic of North Macedonia [Skopje], Ain Shams University (ASU), Sagamihara National Hospital [Kanagawa, Japan], Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Amsterdam UMC - Amsterdam University Medical Center, Universidade do Porto = University of Porto, Wuhan University [China], CHU Grenoble, Silesian University of Medicine, Istanbul Faculty of Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Centre Hospitalier Universitaire de Nice (CHU Nice), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Medizinische Universität Wien = Medical University of Vienna, Aarhus University [Aarhus], Oncology Institute of St Elisabeth, University of Naples Federico II = Università degli studi di Napoli Federico II, St Joseph University, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Kazakh National Medical University, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Tartu University Institute of Clinical Medicine, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], University Medical Center [Utrecht], Semmelweis University [Budapest], Medical University of Łódź (MUL), Vilnius University [Vilnius], University of Medicine and Pharmacy (VIETNAM), University of Cape Town, CHU Sart Tilman, Université de Liège, University of Beira Interior [Portugal] (UBI), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, CHU Montpellier, Wroclaw Medical University [Wrocław, Pologne], University of Bari Aldo Moro (UNIBA), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sagamihara National Hospital, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, Bousquet J., Agache I., Blain H., Jutel M., Ventura M.T., Worm M., Del Giacco S., Benetos A., Bilo B.M., Czarlewski W., Abdul Latiff A.H., Al-Ahmad M., Angier E., Annesi-Maesano I., Atanaskovic-Markovic M., Bachert C., Barbaud A., Bedbrook A., Bennoor K.S., Berghea E.C., Bindslev-Jensen C., Bonini S., Bosnic-Anticevich S., Brockow K., Brussino L., Camargos P., Canonica G.W., Cardona V., Carreiro-Martins P., Carriazo A., Casale T., Caubet J.-C., Cecchi L., Cherubini A., Christoff G., Chu D.K., Cruz A.A., Dokic D., El-Gamal Y., Ebisawa M., Eberlein B., Farrell J., Fernandez-Rivas M., Fokkens W.J., Fonseca J.A., Gao Y., Gavazzi G., Gawlik R., Gelincik A., Gemicioglu B., Gotua M., Guerin O., Haahtela T., Hoffmann-Sommergruber K., Hoffmann H.J., Hofmann M., Hrubisko M., Illario M., Irani C., Ispayeva Z., Ivancevich J.C., Julge K., Kaidashev I., Khaitov M., Knol E., Kraxner H., Kuna P., Kvedariene V., Lauerma A., Le L.T.T., Le Moing V., Levin M., Louis R., Lourenco O., Mahler V., Martin F.C., Matucci A., Milenkovic B., Miot S., Montella E., Morais-Almeida M., Mortz C.G., Mullol J., Namazova-Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Okamoto Y., Ollert M., Palomares O., Papadopoulos N.G., Panzner P., Passalacqua G., Patella V., Petrovic M., Pfaar O., Pham-Thi N., Plavec D., Popov T.A., Recto M.T., Regateiro F.S., Reynes J., Roller-Winsberger R.E., Rolland Y., Romano A., Rondon C., Rottem M., Rouadi P.W., Salles N., Samolinski B., Santos A.F., S Sarquis F., Sastre J., M. G. A. Schols J., Scichilone N., Sediva A., Shamji M.H., Sheikh A., Skypala I., Smolinska S., Sokolowska M., Sousa-Pinto B., Sova M., Stelmach R., Sturm G., Suppli Ulrik C., Todo-Bom A.M., Toppila-Salmi S., Tsiligianni I., Torres M., Untersmayr E., Urrutia Pereira M., Valiulis A., Vitte J., Vultaggio A., Wallace D., Walusiak-Skorupa J., Wang D.-Y., Waserman S., Yorgancioglu A., Yusuf O.M., Zernotti M., Zidarn M., Chivato T., Akdis C.A., Zuberbier T., Klimek L., HUS Inflammation Center, University of Helsinki, and Department of Dermatology, Allergology and Venereology
- Subjects
Male ,Allergy ,Pediatrics ,Eaaci Position Paper ,COVID-19 vaccines ,older (adults ,GUIDELINES ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Medicine and Health Sciences ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,ComputingMilieux_MISCELLANEOUS ,Geriatrics ,MESH: Aged ,RISK ,Vaccines ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,people) ,EPINEPHRINE ,Epinephrine ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,COVID -19 vaccines ,Anaphylaxis ,medicine.drug ,older (adults/people) ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,MESH: Covid-19 ,MESH: Epinephrine ,Immunology ,adrenaline ,anaphylaxis ,Aged ,COVID-19 Vaccines ,Humans ,SARS-CoV-2 ,COVID-19 ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,03 medical and health sciences ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Diabetes mellitus ,Anaphylaxis/etiology ,MESH: SARS-CoV-2 ,[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology ,COVID‐19 vaccines ,Older - Adults/people ,Asthma ,MESH: Humans ,business.industry ,adrenaline, anaphylaxis, COVID-19 vaccines, older (adults/people) ,medicine.disease ,Obesity ,[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology ,MESH: Male ,MESH: Anaphylaxis ,Older ,3121 General medicine, internal medicine and other clinical medicine ,business ,MESH: Covid-19 vaccines ,030215 immunology - Abstract
Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:34:51Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:35:49Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Made available in DSpace on 2021-07-05T13:35:49Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Previous issue date: 2021-04-02 info:eu-repo/semantics/publishedVersion
- Published
- 2021
50. A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial – the PRADA trial
- Author
-
Catherine Droitcourt, Sébastien Barbarot, Annabel Maruani, Laure Darrieux, Laurent Misery, Emilie Brenaut, Henri Adamski, Cécile Chabbert, Annie Vermersch, Marie Weiborn, Julien Seneschal, Alain Taïeb, Patrice Plantin, Hervé Maillard, Alice Phan, François Skowron, Manuelle Viguier, Delphine Staumont-Salle, Audrey Nosbaum, Angèle Soria, Annick Barbaud, Emmanuel Oger, Alain Dupuy, and Groupe de Recherche sur l’Eczéma Atopique de la Société Française de Dermatologie (GREAT)
- Subjects
Atopic dermatitis ,vitamin D ,phototherapy ,long-term control ,add-on therapy ,pragmatic trial ,Medicine (General) ,R5-920 - Abstract
Abstract Background Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term despite long-term control having been acknowledged as one of the most important core outcome domains to be targeted in atopic dermatitis trials. Safe add-on therapies, rigorously evaluated for long-term control of the disease, are therefore needed. Phototherapy and vitamin D supplementation are both good candidates. Methods This is a multicenter, national, randomized, superiority, crossover trial testing add-on phototherapy (one winter under spaced sessions of phototherapy and one winter under observation) among subjects receiving standard care (i.e., TAT). On the same population, we will test the long-term control provided by oral supplementation of vitamin D versus placebo in a randomized, superiority, double-blind, parallel-group trial. The primary outcomes are (1) repeat measures of the PO-SCORAD severity score over 1 year and (2) cumulate consumption of TAT (number of tubes) during the winter. They will be tested following a hierarchical testing procedure. The secondary outcomes will be measures repeated over 2 years of investigator-based severity scores, patient-reported severity and quality of life scores, serum vitamin D levels, weeks during which the disease is well-controlled, inter-visit cumulate consumption of TAT, and synthetic patient-reported satisfaction at the end of each winter. Discussion This study includes two separate 2-year pragmatic trials designed to evaluate the efficacy of vitamin D supplementation and pro-active phototherapy for primary care atopic dermatitis patients receiving TAT on long-term control of disease activity. The experimental design enables the study of both interventions and exploration of the interaction between vitamin D and phototherapy. A pragmatic trial is particularly suited to the assessment of long-term control. This study explores the possibility of new and safe therapeutic strategies for the control of long-term atopic dermatitis, and is an example of efficacy research that is unlikely to be sponsored by industrialists. A potentially effective low-cost therapeutic strategy for long-term control is essential for patients and public health. Trial registration ClinicalTrials.gov Identifier: NCT02537509, first received: 1 September 2015.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.